Overview

Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
To assess the pharmacokinetics, safety and tolerability of a single dose of CAZ-AVI in children from 3 months of age to <18 years.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Pfizer
Collaborator:
Forest Laboratories
Treatments:
Avibactam
Avibactam, ceftazidime drug combination
Ceftazidime